Nephrology · Clinician Reference

The Silent Kidney:
Compensation, Concealment & Renal Plasticity

Why CKD is asymptomatic by mechanism rather than by chance — and what that implies for detection, monitoring, and the windows in which trajectory can still be changed.

PublishedNailathalaGipatikPepalwal: ReferencesMga SanggunianMga TinubdanReng Reperensya: 26 Read timeOras ng pagbasaOras sa pagbasaOras ning pamamasa:
A conceptual nephron with four translucent concealment veils on one side and a four-band plasticity timeline on the other, over a periwinkle clinical field.
Reading as
Patients & Families Clinicians

The thesis

Chronic kidney disease (CKD) is silent because the kidney is plastic. The same adaptation that hides the disease is the adaptation that drives it — and the same adaptive machinery, redirected, is what lets it partly heal.

This reframing collapses two apparently distinct clinical stories — asymptomatic progression and conditional reversibility — into one physiology viewed from two sides. It is organized around two four-part structures: a four-layer model of concealment (reserve depletion → nephron magnification → tubular creatinine hypersecretion → the absent nociceptive route) and a four-window model of plasticity (hemodynamic → cellular-adaptive → maladaptive-not-yet-fixed → established sclerosis). A methodological caution up front: these two structures are not isomorphic. They share a number and nothing else, and mapping a concealment layer onto a plasticity window would be a category error. Where the two connect is Bricker's trade-off hypothesis, which supplies the hinge from silence to plasticity.

Four stacked translucent layers over a nephron labeled reserve spent, survivors magnify, marker compensates, no nociceptive route — each further obscuring the organ from routine testing.

The four-layer concealment model: functional reserve is consumed before resting GFR moves, surviving nephrons magnify per-nephron solute handling, the tubule hypersecretes creatinine onto the diagnostic test itself, and there is no medullary nociceptive route to generate symptoms.

GFR
Glomerular filtration rate.
🔬

How this guide tiers its claims

Claims are separated by strength, and the verbs track the evidence. Established physiology (the intact-nephron adaptations, tubuloglomerular feedback, hyperfiltration) is stated plainly. A claim resting on landmark randomized controlled trials or concordant meta-analyses — "demonstrates." Extrapolation beyond the trial population, or a surrogate standing in for a hard outcome — "supports." An observational relationship — "is associated with." A mechanistic hypothesis, plausible but unproven — "may" or "is hypothesized to." A mechanism is never treated as proof of patient-important benefit: a therapy can move a biomarker (albuminuria, estimated glomerular filtration rate (eGFR) slope) without a demonstrated effect on kidney failure, cardiovascular events, or survival, and wherever that gap exists it is named.

The physiology of concealment

Intact nephron hypothesis. Bricker, Morrin and Kime (1960; restated 1969) established that surviving nephrons retain essential functional integrity as units — increased single-nephron GFR (snGFR), decreased fractional tubular reabsorption, increased tubular secretion, and intact tubuloglomerular feedback (TGF). Homeostasis is maintained by adaptation of the remaining units, not by residual "normal" tissue coexisting with dead tissue.

Magnification phenomenon. Bricker and colleagues (1978) showed that as nephron number falls, each survivor excretes a magnified share of the daily solute load. The plasma value is normal precisely because per-nephron work has become abnormal — the central idea for interpreting any normal plasma value in advancing CKD.

Renal functional reserve (RFR). Bosch (1983) and, in modern synthesis, Mueller and Luyckx (2024) frame RFR as the recruitable increment in GFR above baseline. Quoting the latter verbatim: "a 'normal' serum creatinine or Cystatin C can mask a significant loss of RFR and compensation via hyperfiltration." Donor and challenge studies describe roughly three phenotypes — no recruitable reserve, preserved reserve, and already-hyperfiltering (with a paradoxical fall on protein challenge). RFR is conceptually important and methodologically unsettled; there are no validated cut-points, and the critique that it lacks a standardized protocol is legitimate.

snGFR and endowment. Denic and colleagues (2017) measured, in ~1,400 living donors, a mean of 860,000 ± 370,000 nephrons per kidney — "per kidney" is load-bearing — with snGFR not varying materially with age (<70), sex, or height (≤190 cm). The teaching point: whole-kidney GFR differences in health are largely nephron-number differences; an elevated snGFR is a risk phenotype, not spare capacity.

Absence of a nociceptive route. Renal afferents are densest in the pelvis, present in the cortex, and effectively absent from the medulla; nociception requires ischemia, infection, obstruction or parenchymal injury, with referral over T12–L3. Chronic nephron loss produces atrophy, not distension — so there is no capsular or pelvic stretch to signal. The silence here is the absence of a nociceptive route rather than a suppressed one; capsular distension, sometimes invoked, is not the operative mechanism in chronic loss.

Symptoms cannot stage the disease. Fletcher and colleagues (2022) — 449 studies, 199,147 participants, 62 countries — found fatigue prevalence 70% (95% CI 60–79) in CKD not on kidney replacement therapy (KRT) versus 70% (64–76) on dialysis. The review does not present an estimated glomerular filtration rate (eGFR)–symptom correlation, so it cannot be read as one; the defensible statement is simply that symptom burden is uninformative for stage.

Take-away. A normal plasma value in CKD reflects adapted per-nephron work, not preserved renal mass — read it as evidence of active compensation, not reassurance.

Creatinine hypersecretion — a Bricker adaptation on the diagnostic test

This is the least-appreciated of the four layers, and the only one that operates on the diagnostic test itself. Shemesh and colleagues (1985) studied 171 patients with glomerular disease, comparing creatinine against inulin, DTPA and 19 Å dextran. Fractional clearances relative to inulin: DTPA 1.02 ± 0.14, dextran 0.98 ± 0.13 — neither differing from unity — while creatinine was 1.64 ± 0.05 (p<0.001), reducible toward unity by intravenous cimetidine, with fractional secretion varying inversely with GFR. The authors' conclusion, verbatim: "creatinine is hypersecreted progressively by remnant renal tubules as the disease worsens… attempts to use creatinine as a marker with which to evaluate or monitor glomerulopathic patients will result in gross and unpredictable overestimates of the GFR."

1.64 ± 0.05
Creatinine fractional clearance vs inulin (Shemesh 1985)
11% / 35%
eGFRcys ≥30% below eGFRcr, outpatient / inpatient (Estrella 2025)
HR 1.69
All-cause mortality with that discordance

Muscle-mass dependence and eGFRcr–eGFRcys discordance. Estrella and colleagues (CKD Prognosis Consortium, 2025) found a cystatin C–based estimate ≥30% lower than the creatinine-based estimate in 11% of 821,327 outpatients and 35% of 39,639 inpatients, with mortality 28.4 versus 16.8 per 1,000 person-years (HR 1.69) and excess cardiovascular mortality, atherosclerotic disease, heart failure and KRT.

Guideline positions (KDIGO 2024). Rec 1.1.2.1 (1B): use creatinine-based eGFR; where cystatin C is available, estimate the category from the combination. Rec 1.2.2.1 (1C): use eGFRcr-cys when eGFRcr is less accurate and GFR affects decisions. Practice Point 1.2.2.7: differences between eGFRcr and eGFRcys are informative in both direction and magnitude; the KDIGO Table 2 indication list (low muscle mass, amputation, extremes of body size, vegetarian diet, cirrhosis, malnutrition) names where creatinine misleads.

🔬

Cross-sectionally blind, longitudinally informative

Creatinine is blind cross-sectionally against a population reference interval and considerably less blind longitudinally against the patient's own baseline. This is both the argument for slope-based monitoring and the origin of the patient-facing line "your normal is not the lab's normal." A 2025 preprint re-analysing the Shemesh data argues this explicitly; it remains a preprint and is weighted accordingly rather than as settled literature.

Take-away. Creatinine's overestimate of GFR widens as disease progresses; the reliable signal is the trend against the patient's own baseline, with cystatin C added whenever muscle mass is atypical.

The trade-off hypothesis

Bricker's trade-off hypothesis (1972) holds that homeostasis for a given solute is preserved, as nephrons are lost, only by permitting a sustained rise in a regulating hormone — whose non-renal actions become the disease. The uremic syndrome is, substantially, an endocrinopathy of adaptation rather than simple toxin accumulation.

The modern worked example is fibroblast growth factor 23 (FGF23). In Isakova and colleagues (2011), among 3,879 Chronic Renal Insufficiency Cohort (CRIC) participants with CKD stages 2–4, mean phosphate and median parathyroid hormone (PTH) were in the normal range while median FGF23 was already markedly elevated; high FGF23 was more common than secondary hyperparathyroidism or hyperphosphatemia in every eGFR stratum, and the eGFR threshold at which the FGF23 slope increased was significantly higher than the corresponding PTH threshold. The sequence is FGF23 ↑ → calcitriol ↓ → PTH ↑ → phosphate ↑, with phosphate last. Only the sequence is established; the specific eGFR values at which each hormone inflects are not, and are best left unquantified.

💡

The unifying principle

The glomerular parallel completes the loop: hyperfiltration is the same bargain expressed hemodynamically — total GFR preserved at the cost of glomerular capillary hypertension, podocyte stress, and the sclerosis it is compensating for. The compensation is the engine. A normal phosphate, like a normal creatinine, is not evidence of quiescence; it is evidence of work.

Concealment at the population scale

87%
US adults with CKD who are unaware (CDC, NHANES 2021–2023)
49.6%
Awareness at ≥15% 5-yr kidney-failure risk (Chu 2020)
17.5%
Urine albumin-to-creatinine ratio (uACR) testing in at-risk adults (Chu 2023)
−3.20 → −0.74
eGFR slope (mL/min/1.73 m²/yr) after diagnosis recorded (REVEAL-CKD)

The concealment described mechanistically above is measurable epidemiologically. In the United States, CKD prevalence is ~14% (37 million) with ~87% unaware; awareness has not improved over two decades (9.4% in 1999 → 10.8% in 2020, non-significant; Ozieh 2025). Awareness rises with risk but tops out at 49.6% even among those at ≥15% five-year kidney-failure risk (Chu 2020). Undiagnosed stage 3 ranges from 64.3% (USA) to 95.5% (France) across five countries, and the missed phenotype is precisely the quietly-compensating patient — female sex, stage 3a, and absence of diabetes or hypertension (Tangri, BMJ Open 2023).

The test that sees through the silence — the urine albumin-to-creatinine ratio (uACR) — is ordered in only 17.5% of at-risk adults overall (52.3% with diabetes, 5.1% in hypertension without diabetes; Chu 2023), and the undetected-to-detected albuminuria ratio is 1.8:1 in diabetes versus 19.5:1 in hypertension (Shin 2021). Up to ~40% of the CKD population is albuminuria-only with a normal eGFR (a figure Chu carries from prior literature rather than a primary measurement, and best cited as such).

Does detection change outcomes? REVEAL-CKD (Tangri, Advances in Therapy 2023): after a stage-3 diagnosis was recorded, angiotensin-converting enzyme inhibitor (ACEi) use rose (RR 1.87), angiotensin receptor blocker (ARB) use rose (RR 1.91), mineralocorticoid receptor antagonist (MRA) use rose (RR 2.23); annual eGFR decline moved from −3.20 to −0.74; rapid decliners fell from 47.1% to 39.2%. Per year of diagnostic delay: progression HR 1.40 (1.31–1.49), kidney failure HR 1.63 (1.23–2.18). Yet uACR monitoring only doubled to 0.05 measurements per person-year — recognition improves care from appalling to poor. Early nephrology referral is associated with lower mortality (Smart & Titus 2011; OR 0.51 at 3 months, 0.45 at 5 years).

🔬

What the screening evidence does and does not support

KDIGO frames case-finding as a practice point — "test people at risk for and with CKD using both urine albumin measurement and assessment of GFR" (PP 1.1.1.1) — not a graded 1A population-screening recommendation, and it should not be represented as one. The United States Preventive Services Task Force (USPSTF) 2012 "I" statement remains operative as of August 2026 (the topic sits at Stage 2 with no draft). Cusick and colleagues (2023) modeled one-time screening at age 55 with sodium-glucose cotransporter-2 (SGLT2) inhibitor treatment at $86,300 per quality-adjusted life-year (QALY). On balance, there is no randomized controlled trial (RCT) showing CKD screening improves hard outcomes, while the observational and modeling support is strong — both halves belong in any honest summary.

Paired bars: uACR ordered in 52% of diabetes versus 5% of hypertension, and undetected-to-detected albuminuria of 1.8 to 1 in diabetes versus 19.5 to 1 in hypertension.

The detection gap. uACR is ordered in ~52% of at-risk patients with diabetes but only ~5% of those with hypertension alone; undetected-to-detected albuminuria runs 1.8:1 in diabetes versus 19.5:1 in hypertension — the hypertensive CKD population is nearly invisible in practice.

uACR
Urine albumin-to-creatinine ratio.

Take-away. Order eGFR and uACR together in every at-risk patient — a recorded diagnosis, more than any single drug, is what most bends the slope. Case-finding the at-risk is supported; population screening is not yet a graded recommendation. Don't conflate the two.

The four windows of plasticity

AxisTimescaleReversibilitySubstrateClinical read-out
1 · HemodynamicMinutes → weeksFully reversibleAfferent/efferent tone, TGF resetting, reserve recruitmentThe eGFR "dip" after a sodium-glucose cotransporter-2 inhibitor (SGLT2i) / renin–angiotensin system (RAS) blockade / MRA / endothelin receptor antagonist (ERA) / BP intensification
2 · Cellular-adaptiveWeeks → monthsLargely reversibleTubular dedifferentiation → redifferentiation (SOX9, Wnt/β-catenin); podocyte foot-process recoveryRecovery within the acute kidney disease (AKD) window; proteinuric remission
3 · Maladaptive, not yet fixedMonths → yearsPartly reversibleFailed-repair proximal tubule cells (FR-PTC), G2/M arrest, senescence, capillary rarefaction, FAO/PGC-1α failure, early fibrosisBending the chronic eGFR slope; albuminuria regression
4 · Established sclerosisYearsOnly if the insult is completely removedGlomerulosclerosis, mature interstitial collagenFioretto's 10-year pancreas-transplant biopsies
— Nephron numberNever regeneratedNephrogenesis ends at 34–36 weeks' gestationEndowment fixed; only per-nephron architecture recovers

Axis 1 — hemodynamic. [Established physiology; the acute dip is directly measured and fully reversible.] The acute eGFR dip on starting an SGLT2 inhibitor, RAS blocker, non-steroidal MRA or endothelin antagonist is de-hyperfiltration: restoration of TGF and reduction of glomerular capillary pressure, not injury. KDIGO PP 2.1.4 anchors the >30% threshold for evaluation. In EMPA-KIDNEY the acute dip averaged −2.12 (1.83–2.41) mL/min/1.73 m² and the subsequent chronic slope difference was ~50%.

Axis 2 — cellular repair. [Established in experimental models; the human corollary — full recovery after acute kidney injury (AKI) — is strongly supported but largely inferential.] Proximal tubule cells dedifferentiate and redifferentiate after injury (SOX9- and Wnt/β-catenin-dependent programs); complete repair restores function. The fork between adaptive repair and the failed-repair state is where trajectory is set.

Axis 3 — maladaptive repair, acute kidney injury (AKI) → CKD. [Mechanistic — chiefly from experimental models; the therapeutic corollary in humans is inference, and the drug targets are pre-clinical.] FR-PTC arrested in G2/M drive a pro-fibrotic secretome; senescence, peritubular capillary rarefaction and fatty-acid-oxidation/PGC-1α failure entrench it. The ADQI-16 acute kidney disease (AKD) construct names the actionable 7–90-day window between acute kidney injury (AKI) and CKD. Return of creatinine to baseline after AKI does not exclude nephron loss — Layer 1 of the concealment model recurring post-AKI, and the mechanistic argument for uACR plus follow-up eGFR rather than a single reassuring creatinine.

Axis 4 — structural regression. [Demonstrated in a single small human series under extreme conditions; not generalizable to routine care.] Fioretto and colleagues (1998): eight patients with type 1 diabetes and isolated pancreas transplantation showed no improvement at 5 years but substantial reversal of glomerular and tubular lesions at 10 years, with urine albumin falling ~103 → 30 → 20 mg/day. The condition is complete, sustained removal of the insult over more than five years — and creatinine clearance still declined even as structure improved. The morphometric detail is best described qualitatively; the exact GBM/mesangial values are not independently verified.

An injured proximal tubule cell at a fork — one path redifferentiates to a healthy tubule, the other becomes a failed-repair cell in G2/M arrest that drives a fibroblast to lay down scar — with the 7–90-day window as the intervention point.

The injured proximal tubule at a fork: redifferentiation restores a functional tubule, while the failed-repair path (G2/M arrest, senescence, a pro-fibrotic secretome) drives interstitial fibrosis. Removing the insult inside the AKD window is where the fork is decided.

FR-PTC
Failed-repair proximal tubule cell.
AKD
Acute kidney disease (7–90 days).
FAO
Fatty-acid oxidation.

Take-away. Reversibility is window-dependent: the hemodynamic and cellular windows close within weeks to months, while the maladaptive window stays open for years. Remaining on therapy therefore matters more than starting it quickly — and creatinine back to baseline after AKI does not confirm recovery.

Nephron endowment and podocyte thresholds

Podocyte plasticity is bounded: experimental depletion studies (Wharram model) demonstrate threshold effects — modest loss is compensated by hypertrophy and foot-process remodelling, but beyond a threshold (~20–40% depending on model) segmental glomerulosclerosis and irreversible loss follow, because podocytes are terminally differentiated and minimally proliferative. Endowment sets the denominator: nephrogenesis ceases at 34–36 weeks, low birth weight and prematurity reduce endowment, and the Denic donor data anchor the mean at 860,000 ± 370,000 per kidney. The clinical corollary is that "reversibility" always operates on per-nephron architecture and never on nephron count.

Take-away. Every intervention acts on per-nephron architecture and function — never on nephron number, which is fixed at birth. Whenever you say "reversible," mean per-nephron.

Redirecting the machinery: the evidence stack

The therapeutics that bend the slope all act by reducing maladaptive hyperfiltration and its downstream signaling. Foundational RAS blockade at maximally tolerated dose plus an SGLT2 inhibitor; non-steroidal MRA and glucagon-like peptide-1 (GLP-1)-based therapy layered above; lifestyle as the base. Selected confirmed effect sizes:

TrialAgent / classPrimary kidney outcomeSlope / albuminuria
EMPA-KIDNEY (2023)Empagliflozin (SGLT2i)HR 0.72 (0.64–0.82)Acute dip −2.12; chronic slope −2.75 → −1.37 (≈50% relative)
DAPA-CKD (2020)Dapagliflozin (SGLT2i)HR 0.61 (0.51–0.72)Effect across diabetic and non-diabetic CKD
CREDENCE (2019)Canagliflozin (SGLT2i)HR 0.70 (0.59–0.82)uACR −31%
FLOW (2024)Semaglutide (GLP-1)HR 0.76 (0.66–0.88)Slope benefit +1.16 mL/min/1.73 m²/yr
FIDELITY (2022)Finerenone (nsMRA)Kidney composite HR 0.77 (0.67–0.88)Additive on RAS + SGLT2i background

From relative to absolute — and how we know. These hazard ratios carry weight because they rest on landmark randomized controlled trials with hard kidney and cardiovascular endpoints, not surrogates. In absolute terms the per-patient effect is meaningful but not dramatic: in EMPA-KIDNEY the primary composite occurred in ~13.1% on empagliflozin versus ~16.9% on placebo over a median 2 years (absolute risk reduction ~3.8 percentage points; number needed to treat ~26), and in DAPA-CKD ~9.2% versus ~14.5% over ~2.4 years (absolute risk reduction ~5.3 points; number needed to treat ~19). These are the figures to quote to a patient weighing a new medication — the relative "halving of decline" is real, but its absolute yield scales with baseline risk, which is why benefit is largest at higher albuminuria and faster decline. (Confirm exact event rates against each trial before quoting to two significant figures.)

Mechanism → evidence → application. Physiologically, each agent lowers intraglomerular pressure — SGLT2 inhibition restores tubuloglomerular feedback through increased distal sodium delivery; RAS blockade dilates the efferent arteriole; non-steroidal MRAs blunt aldosterone-driven inflammation and fibrosis. That mechanism is established physiology. That these agents slow measured kidney-failure endpoints is strong clinical evidence from multiple concordant trials. That the same benefit accrues in an under-represented subgroup — very low eGFR, minimal albuminuria, the frail elderly — is evidence-supported inference: reasonable, not proven. Those three tiers should stay distinct at the bedside.

Sequencing. RAS blockade to maximally tolerated dose → SGLT2 inhibitor (eGFR ≥20) → if uACR ≥30 mg/g persists, add a non-steroidal MRA (eGFR ≥25, K⁺ ≤5.0) and/or GLP-1-based therapy → reassess uACR at 4 and 12 weeks, targeting ≥30% reduction. The CONFIDENCE trial (2025) supports combined RAS + SGLT2i + finerenone with greater albuminuria reduction; its per-arm hyperkalemia rates reflect a high-risk subgroup and should not be read as trial-wide. American Diabetes Association (ADA) 2026 §11 endorses more simultaneous, rather than strictly sequential, initiation in high-risk patients. Maintenance dependency is intrinsic: post-trial washout data (EMPA-KIDNEY) show benefit largely converging within ~6–12 months of stopping — disease modification requiring maintenance, not a reset.

⚕️

Consistency points worth carrying into practice

SGLT2 inhibitor eligibility is not diabetes-gated (KDIGO Rec 3.7.2, 1A; EMPA-KIDNEY was 54% non-diabetic). "Four pillars" is commentary vocabulary, not KDIGO's — attribute to the comprehensive-strategy concept (PP 3.1.1). Potassium management: restrict the additive, liberalise the plant; salt substitutes are potassium chloride. Protein restriction always carries its sarcopenia counterweight. Race-free eGFR (CKD-EPI 2021) with cystatin C where creatinine misleads. Anemia language follows KDIGO 2026 (systemic iron deficiency / iron-restricted erythropoiesis; ESA rather than HIF-PHI first-line, 2D).

A layered stack — lifestyle at the base, RAS blockade plus an SGLT2 inhibitor as the foundation, and a non-steroidal MRA or GLP-1-based therapy layered on top when protein leak persists — each layer taking pressure off the surviving filters.

The therapy stack redirects the same adaptive machinery: lifestyle at the base, RAS blockade plus an SGLT2 inhibitor as the foundation, and a non-steroidal MRA and/or GLP-1-based therapy added when albuminuria persists — layers, not a KDIGO "pillars" hierarchy.

Take-away. Each agent bends the slope by de-hyperfiltration, and the benefit is maintenance-dependent — disease modification requiring continuation, not a cure. Build up from the lifestyle base; treat "pillars" as commentary, not KDIGO's own framing.

The Philippine argument

The concealment thesis has a sharp Philippine edge. Reported dialysis census rose from 53,296 (2023) to 64,845 (2024) — a 22% single-year increase — and the leading causes of end-stage kidney disease (ESKD) are hypertensive nephrosclerosis (33.07%) ahead of diabetic nephropathy (30.04%), i.e. a predominantly screening-detectable population (these figures are carried via society communications rather than a primary registry release, and are best cited as such pending the primary NKTI/Philippine Renal Disease Registry report). Estimated CKD prevalence is 10.2 million cases (9.5–11.1; Makmun 2025) — and that same source states ESKD incidence data are unavailable for the Philippines. That registry gap is itself a research and advocacy priority — better named than filled with a news-derived per-million figure.

💡

The screening asymmetry

PhilHealth (the Philippine Health Insurance Corporation) reimburses up to ₱990,600 per patient per year for dialysis (156 sessions × ₱6,350), while the creatinine-and-urine-albumin pair that could have identified the same patient a decade earlier sits outside its screening packages. KDIGO Rec 1.4.1 (2C) — point-of-care testing (POCT) for creatinine and urine albumin where laboratory access is limited — is the implementable answer for provincial practice. (The "screening not covered" claim currently rests on a society statement and warrants confirmation against a current PhilHealth circular.)

Clinical decision algorithms

ALG-1 · Managing the eGFR dip
1
Start SGLT2i / RAS blocker / nsMRA / ERA, or intensify BP → recheck creatinine + K⁺ at 2–4 weeks.
2
Fall ≤30%, K⁺ acceptable: continue at full dose; recheck per routine. Counsel that this is de-hyperfiltration, not injury.
3
Fall >30% (KDIGO PP 2.1.4): evaluate before any dose change — volume depletion, non-steroidal anti-inflammatory drug (NSAID), diuretic excess, intercurrent illness, renovascular disease. Correct the reversible cause; recheck 1–2 weeks. Persistent >30% with no cause → reduce or hold, then rechallenge once stable.
4
K⁺ >5.5 mmol/L: additive-first dietary review, loop-diuretic optimisation, consider a binder to preserve RAS blockade / nsMRA at target dose. Do not default to stopping the RAS blocker.
ALG-2 · Post-AKI (AKD) 90-day protocol
1
Nephrotoxin reconciliation; contrast planning; normalize volume and BP.
2
Repeat eGFR and uACR at weeks 3–12; apply referral criteria; reassess dialysis dependence explicitly.
3
Carry the caveat: creatinine back to baseline ≠ nephron recovery; the reserve may be spent even when the number normalizes.
ALG-3 · Sequencing the stack
1
RAS blockade to maximally tolerated dose → add an SGLT2 inhibitor once eGFR ≥20.
2
If uACR ≥30 mg/g persists, add a non-steroidal MRA (eGFR ≥25, K⁺ ≤5.0) and/or GLP-1-based therapy.
3
Reassess uACR at 4 and 12 weeks, targeting ≥30% reduction; up-titrate or add the next agent if the target is unmet.
4
Parallel branch (ADA 2026 §11): in high-risk patients, more simultaneous rather than strictly sequential initiation is reasonable.
ALG-4 · Choosing the read-out
1
"Is it working?" → uACR at 4–12 weeks (the fastest-moving signal).
2
"What's the trajectory?" → eGFR slope over ≥1 year, ≥3 points.
3
"What's the risk?" → the Kidney Failure Risk Equation (KFRE).
4
"Is creatinine misleading me?" → cystatin C (any KDIGO Table 2 indication).
ALG-5 · Who to test, with what
1
Risk trigger — diabetes, hypertension, cardiovascular disease (CVD), family history, age ≥60, obesity, prior AKI, or low birth weight.
2
eGFR and uACR together, never eGFR alone; confirm abnormal results on repeat.
3
Add cystatin C if any KDIGO Table 2 indication; stage by both axes; compute the Kidney Failure Risk Equation (KFRE) if G3–G5. Use the POCT branch (Rec 1.4.1) where laboratory access is limited.

Axis 3, becoming druggable

The frontier is pharmacological access to maladaptive repair. Candidate approaches: autologous cell therapy (e.g. rilparencel) — interpret against strong regression-to-the-mean pressure in slope endpoints and early-phase, uncontrolled designs; aldosterone synthase inhibition; endothelin-A antagonism (with fluid-retention mitigation); and senolytic / FR-PTC-directed strategies aimed squarely at the G2/M-arrested, senescent tubular population. None yet warrants clinical adoption outside trials; frame them as "axis 3 becoming targetable," not as available therapy.

Take-away. Axis 3 is becoming druggable, but none of these approaches is standard care — present them to patients and colleagues as trial-stage, not available therapy.

What this framework does not license

💡

Patient-facing companion

The lay-register version of this material — same physiology, grade 8–10 reading level, with the dip explainer and the five levers — is Why Kidney Disease Is Silent →. Reciprocal, self-canonicalising, not duplicate content.

Points of confusion, resolved

Is "50% of function lost before creatinine rises" safe to teach?
No — there is no primary source stating it as a measured quantity. The defensible equivalent is that a single creatinine value can correspond to a measured GFR from roughly 30 to 90 mL/min/1.73 m², i.e. creatinine is insensitive above ~60, and rely on the trend against the patient's own baseline.
Does a normal creatinine after AKI confirm recovery?
No. Reserve may be spent while the resting value normalizes. Follow with uACR and serial eGFR through the AKD window (7–90 days); creatinine back to baseline does not exclude nephron loss.
Should the eGFR dip on an SGLT2 inhibitor prompt discontinuation?
Not for a ≤30% fall with acceptable potassium — that is de-hyperfiltration. Evaluate a >30% fall (KDIGO PP 2.1.4) for reversible causes; recheck at 2–4 weeks. Injury markers do not rise during the equivalent pressure-mediated dip.
Is SGLT2 inhibitor therapy limited to diabetic CKD?
No. KDIGO Rec 3.7.2 (1A) covers CKD with eGFR ≥20 and uACR ≥200 mg/g, or heart failure irrespective of albuminuria; EMPA-KIDNEY was 54% non-diabetic.
Glossary & abbreviations terms used in this guide

Abbreviations

ACEi
Angiotensin-converting enzyme inhibitor.
ADA
American Diabetes Association.
AKD
Acute kidney disease — the 7-to-90-day post-injury window (ADQI-16).
AKI
Acute kidney injury.
ARB
Angiotensin receptor blocker.
CKD
Chronic kidney disease.
CRIC
Chronic Renal Insufficiency Cohort.
CVD
Cardiovascular disease.
eGFR
Estimated glomerular filtration rate (creatinine-based unless specified).
ERA
Endothelin receptor antagonist.
FGF23
Fibroblast growth factor 23.
FR-PTC
Failed-repair proximal tubule cell — a G2/M-arrested, pro-fibrotic tubular phenotype.
GLP-1
Glucagon-like peptide-1 (receptor agonist class).
KDIGO
Kidney Disease: Improving Global Outcomes.
KFRE
Kidney Failure Risk Equation.
KRT
Kidney replacement therapy.
MRA
Mineralocorticoid receptor antagonist (nsMRA = non-steroidal, e.g. finerenone).
NSAID
Non-steroidal anti-inflammatory drug.
POCT
Point-of-care testing.
PTH
Parathyroid hormone.
QALY
Quality-adjusted life-year.
RCT
Randomized controlled trial.
RFR
Renal functional reserve — recruitable GFR increment above baseline.
RAS
Renin–angiotensin system (RAS blockade = ACEi or ARB).
SGLT2i
Sodium-glucose cotransporter-2 inhibitor.
snGFR
Single-nephron glomerular filtration rate.
TGF
Tubuloglomerular feedback.
uACR
Urine albumin-to-creatinine ratio.
USPSTF
United States Preventive Services Task Force.

Terms

De-hyperfiltration
The intended reduction of glomerular capillary pressure by RAS blockade or an SGLT2 inhibitor, producing the reversible acute eGFR dip.
Intact nephron hypothesis
Bricker's principle that surviving nephrons function as integrated units with adapted per-nephron handling.
Magnification phenomenon
Each surviving nephron excreting a magnified share of the daily solute load, keeping plasma values normal.
Trade-off hypothesis
Homeostasis preserved only by a sustained rise in a regulating hormone whose non-renal actions become the disease.
Podocyte depletion threshold
The proportion of podocyte loss beyond which segmental sclerosis becomes inevitable (terminally differentiated cells).
Regression to the mean
The statistical tendency of extreme baseline slopes to appear to improve on re-measurement — a confounder in single-arm cell-therapy studies.
References 26 sources
  1. Shemesh, O., Golbetz, H., Kriss, J. P., & Myers, B. D. (1985). Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney International, 28(5), 830–838. https://doi.org/10.1038/ki.1985.205
  2. Bricker, N. S., Morrin, P. A. F., & Kime, S. W. (1960). The pathologic physiology of chronic Bright's disease: An exposition of the "intact nephron hypothesis." The American Journal of Medicine, 28(1), 77–98. https://pubmed.ncbi.nlm.nih.gov/13804370/
  3. Bricker, N. S. (1969). On the meaning of the intact nephron hypothesis. The American Journal of Medicine, 46(1), 1–11. https://pubmed.ncbi.nlm.nih.gov/4952757/
  4. Bricker, N. S., Fine, L. G., Kaplan, M., Epstein, M., Bourgoignie, J. J., & Licht, A. (1978). "Magnification phenomenon" in chronic renal disease. The New England Journal of Medicine, 299(23), 1287–1293. https://pubmed.ncbi.nlm.nih.gov/714096/
  5. Bricker, N. S. (1972). On the pathogenesis of the uremic state: An exposition of the "trade-off hypothesis." The New England Journal of Medicine, 286(20), 1093–1099. https://pubmed.ncbi.nlm.nih.gov/4553202/
  6. Bosch, J. P., Saccaggi, A., Lauer, A., Ronco, C., Belledonne, M., & Glabman, S. (1983). Renal functional reserve in humans: Effect of protein intake on glomerular filtration rate. The American Journal of Medicine, 75(6), 943–950. https://pubmed.ncbi.nlm.nih.gov/6650549/
  7. Mueller, T. F., & Luyckx, V. A. (2024). Renal functional reserve: Compensation, concealment and clinical implications. Current Opinion in Nephrology and Hypertension, 33(1), 130–135. https://doi.org/10.1097/MNH.0000000000000930
  8. Denic, A., Mathew, J., Lerman, L. O., Lieske, J. C., Larson, J. J., Alexander, M. P., Poggio, E., Glassock, R. J., & Rule, A. D. (2017). Single-nephron glomerular filtration rate in healthy adults. The New England Journal of Medicine, 376(24), 2349–2357. https://doi.org/10.1056/NEJMoa1614329
  9. Fletcher, B. R., Damery, S., Aiyegbusi, O. L., Anderson, N., Calvert, M., Cockwell, P., Ferguson, J., Horton, M., Paap, M. C. S., Sidey-Gibbons, C., Slade, A., Turner, N., & Kyte, D. (2022). Symptom burden and health-related quality of life in chronic kidney disease: A global systematic review and meta-analysis. PLOS Medicine, 19(4), e1003954. https://doi.org/10.1371/journal.pmed.1003954
  10. Isakova, T., Wahl, P., Vargas, G. S., Gutiérrez, O. M., Scialla, J., Xie, H., Wolf, M., & the Chronic Renal Insufficiency Cohort (CRIC) Study Group. (2011). Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney International, 79(12), 1370–1378. https://doi.org/10.1038/ki.2011.47
  11. Estrella, M. M., Ku, E., Shlipak, M. G., & the CKD Prognosis Consortium. (2025). Discordance between creatinine- and cystatin C–based estimated glomerular filtration rate and adverse clinical outcomes. JAMA, 334(21), 1915–1926. https://pubmed.ncbi.nlm.nih.gov/41202182/
  12. Centers for Disease Control and Prevention (CDC). (2024). Chronic kidney disease in the United States, 2024. U.S. Department of Health and Human Services. https://www.cdc.gov/kidney-disease/php/data-research/
  13. Ozieh, M. N., Egede, L. E., & colleagues. (2025). Trends in awareness of chronic kidney disease among US adults, 1999–2020. American Journal of Nephrology. Advance online publication. https://pubmed.ncbi.nlm.nih.gov/41201991/
  14. Chu, C. D., McCulloch, C. E., Banerjee, T., Pavkov, M. E., Burrows, N. R., Gillespie, B. W., Saran, R., Shlipak, M. G., Powe, N. R., & Tuot, D. S. (2020). CKD awareness among US adults by future risk of kidney failure. American Journal of Kidney Diseases, 76(2), 174–183. https://doi.org/10.1053/j.ajkd.2020.01.007
  15. Tangri, N., Moriyama, T., Schneider, M. P., Virgitti, J. B., De Nicola, L., Arnold, M., Barratt, J., Chukwuma, F., & Pecoits-Filho, R. (2023). Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: The REVEAL-CKD study. BMJ Open, 13(5), e067386. https://pubmed.ncbi.nlm.nih.gov/37217263/
  16. Tangri, N., Peach, E. J., Franzén, S., Barone, S., & Kushner, P. R. (2023). Patient management and clinical outcomes associated with a recorded diagnosis of stage 3 chronic kidney disease: The REVEAL-CKD study. Advances in Therapy, 40(6), 2869–2885. https://doi.org/10.1007/s12325-023-02482-5
  17. Chu, C. D., Powe, N. R., Shlipak, M. G., Scherzer, R., Tummalapalli, S. L., Estrella, M. M., & Tuot, D. S. (2023). Albuminuria testing and nephrology care among insured US adults with chronic kidney disease. JAMA Network Open, 6(7), e2326230. https://pubmed.ncbi.nlm.nih.gov/37498594/
  18. Shin, J.-I., Chang, A. R., Grams, M. E., Coresh, J., Ballew, S. H., Surapaneni, A., Matsushita, K., & the CKD Prognosis Consortium. (2021). Albuminuria testing in hypertension and diabetes: An individual-participant data meta-analysis. Hypertension, 78(4), 1042–1052. https://doi.org/10.1161/HYPERTENSIONAHA.121.17323
  19. Smart, N. A., & Titus, T. T. (2011). Outcomes of early versus late nephrology referral in chronic kidney disease: A systematic review. The American Journal of Medicine, 124(11), 1073–1080. https://doi.org/10.1016/j.amjmed.2011.04.026
  20. Cusick, M. M., Tisdale, R. L., Chertow, G. M., Owens, D. K., & Goldhaber-Fiebert, J. D. (2023). Population-wide screening for chronic kidney disease: A cost-effectiveness analysis. Annals of Internal Medicine, 176(6), 788–797. https://pubmed.ncbi.nlm.nih.gov/37216661/
  21. Perkins, B. A., Ficociello, L. H., Silva, K. H., Finkelstein, D. M., Warram, J. H., & Krolewski, A. S. (2003). Regression of microalbuminuria in type 1 diabetes. The New England Journal of Medicine, 348(23), 2285–2293. https://doi.org/10.1056/NEJMoa021835
  22. Fioretto, P., Steffes, M. W., Sutherland, D. E. R., Goetz, F. C., & Mauer, M. (1998). Reversal of lesions of diabetic nephropathy after pancreas transplantation. The New England Journal of Medicine, 339(2), 69–75. https://doi.org/10.1056/NEJM199807093390202
  23. Herrington, W. G., Staplin, N., Wanner, C., Green, J. B., & the EMPA-KIDNEY Collaborative Group. (2023). Empagliflozin in patients with chronic kidney disease. The New England Journal of Medicine, 388(2), 117–127. https://doi.org/10.1056/NEJMoa2204233
  24. Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., Sjöström, C. D., Toto, R. D., Langkilde, A.-M., & Wheeler, D. C. (2020). Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). The New England Journal of Medicine, 383(15), 1436–1446. https://doi.org/10.1056/NEJMoa2024816
  25. Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Cannon, C. P., Capuano, G., Chu, P.-L., de Zeeuw, D., Greene, T., Levin, A., Pollock, C., Wheeler, D. C., Yavin, Y., … Mahaffey, K. W. (2019). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE). The New England Journal of Medicine, 380(24), 2295–2306. https://doi.org/10.1056/NEJMoa1811744
  26. Makmun, A., Kooman, J. P., & Usvyat, L. A. (2025). Chronic kidney disease burden and care gaps in Southeast Asia. Kidney Research and Clinical Practice, 44(3), 411–433. https://doi.org/10.23876/j.krcp.23.194
Dr. W Rivero, MD

W Rivero, MD, FPCP, DPSN

Specialist in Internal Medicine, Nephrology, and Clinical Nutrition. Practicing integrative and evidence-based nephrology across Quezon City, Pampanga, and Bulacan.

· Book an Appointment →

QR code — scan to save Dr. Rivero's contact info

Scan and save